Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1941-1950

  Panades, Miguel ^a   Olivotto, Ivo A ^a   Speers, Caroline H ^a   Shenkier, Tamara ^a   Olivotto, Theodora A ^a   Weir, Lorna ^a   Allan, Sharon J ^a   Truong, Pauline T ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; BREAST TUMOR; CANADA; HEALTH SURVEY; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRITISH COLUMBIA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 15744378538     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.233     Document Type: Article

References (30)

1. Levine PH, Steinhorn SC, Ries LG, et al: Inflammatory breast cancer: The experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 74:291-297, 1985
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G, et al: Inflammatory breast cancer: A review. J Clin Oncol 10:1014-1024, 1992
3. Ueno NT, Buzdar AU, Singletary SE, et al: Combined-modality treatment of inflammatory breast cancer: Twenty years of experience at MD Anderson Cancer Center. Chemother Pharm 40:321-329, 1997
4. Liauw SL, Benda RK, Morris CG, et al: Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease. Cancer 100:920-928, 2004
5. Chang S, Parker SL, Pham T, et al: Inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology and End Results program of the National Cancer Institute, 1975-1992. Cancer 82:2366-2372, 1998
6. Low JA, Berman AW, Steinberg SM, et al: Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 22:4067-4074, 2004
7. Perez CA, Fields JN, Fracasso PM, et al: Management of locally advanced carcinoma of the breast: II. Inflammatory carcinoma. Cancer 74:466-476, 1994
8. Therasse P, Mauriac L, Welmicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850, 2003
9. British Columbia Cancer Agency: Management-Inflammatory breast cancer, BC Cancer Agency, 2003. http://www.bccancer.be .ca/HPI/CancerManagementGuidelines/ Breast/ Management/Inflammatory.htm
10. Shenkier T, Weir L, Levine MN, et al: Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ 170:983-994, 2004
11. American Joint Committee on Cancer: AJCC Cancer Staging Handbook (ed 5). Philadelphia, PA, Lippincott-Raven, 1998, p 172
12. Ragaz J, Manji M, Plenderleith IH, et al: Impact of residual disease in stage III breast cancer patients treated with preoperative (neoadjuvant) chemotherapy, radiotherapy and mastectomy: The 10-year analysis of the British Columbia study. Proc Am Soc Clin Oncol 13:71a, 1994 (abstr 88)
13. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998
14. Shenkier TN, O'Reilly S, Gelmon K, et al: A phase II trial of two different sequences of neoadjuvant doxorubicin/paclitaxel (AT) and cisplatin/paclitaxel (CT) in patients with locally advanced breast cancer: Expression of markers of resistance over time. Breast Cancer Res Treat 82:557, 2003 (abstr 246)
15. O'Reilly SE, Gelman KA, Tolcher AW, et al: Comparison of outcomes in high risk, locally advanced and inflammatory breast cancer treated with investigational high dose chemotherapy (Quartet) versus recipients of standard doxorubicin-based regimens. Proc Am Soc Clin Oncol 18:85a, 1999 (abstr 323)
16. Fleming RY, Asmar L, Buzdar AU, et al: Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 4:452-461, 1997
17. Schafer P, Alberto P, Forni M, et al: Surgery as part of a combined modality approach for inflammatory breast carcinoma. Cancer 59:1063-1067, 1987
18. Brun B, Otmezguine Y, Feuilhade F, et al: Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation. Cancer 61:1096-1103, 1988
19. De Boer RH, Allum WH, Ebbs SR, et al: Multimodality therapy in inflammatory breast cancer: Is there a place for surgery? Ann Oncol 11:1147-1153, 2000
20. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
21. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
22. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
23. Henderson C, Berry D, Demetri G, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
24. Crown JP, Lind M, Gould A, et al: High-dose chemotherapy with autograft support is not superior to cyclophosphamide, methotrexate and 5-FU following doxorubicin induction in patients with breast cancer and four or more involved axillary lymph nodes. Proc Am Soc Clin Oncol 20:42, 2002 (abstr 166)
25. Bertucci F, Tarpin C, Charafe-Jauffret E, et al: Multivariate analysis of survival in inflammatory breast cancer: Impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant 33:913-920, 2004
26. Brito RA, Valero V, Buzdar AU, et al: Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 19:628-633, 2001
27. Olivotto IA, Chua B, Allan SJ, et al: Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol 21:851-854, 2003
28. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636, 2002
29. Fisher B, Bryant J, Wolmak N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
30. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999